drugset / Trial / NCT02769104
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The investigators designed this study to investigate the effect of aromatase inhibitors (AI) plus chemotherapy versus chemotherapy as neoadjuvant treatment in postmenopausal hormone receptor-positive breast cancer.
Timeline
- Start
- 2016-05
- Primary completion
- 2018-07
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letrozole | Other / unclassified | 2.5 mg | Oral |
| Background | CTX | Unknown | 800 mg/m2 | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |
Indications
No indication recorded.